Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Publication year range
1.
Int J Biol Markers ; 23(3): 192-7, 2008.
Article in English | MEDLINE | ID: mdl-18949747

ABSTRACT

AIM: To determine whether urinary concentrations of phytoestrogens are associated with the rate of disease progression in men with untreated, localised prostate cancer. PATIENTS AND METHODS: Patients with untreated, localised prostatic adenocarcinoma on a prospective clinical study of active surveillance had urine samples collected at baseline. Patients underwent monitoring with serial PSA levels and repeat octant prostate biopsies. Disease progression was defined as either adverse histology on repeat biopsy (primary Gleason grade >or= 4, or >50% positive cores) or radical treatment for PSA velocity >1 ng/mL/year. Time to disease progression was analysed with respect to baseline urinary levels of genistein, enterolactone, daidzein and equol, assayed using liquid chromatography/tandem mass spectrometry. RESULTS: 191 patients were evaluable, with a median follow-up of 2.5 years. 71 patients experienced disease progression. No significant association was seen between time to disease progression and baseline urinary levels of daidzein (p=0.85), genistein (p=0.81), enterolactone (p=0.085) or equol (p=0.33). No significant association was seen between adverse histology on repeat biopsy and urinary levels of either daidzein (p=0.85), genistein (p=0.58), enterolactone (p=0.88) or equol (p=0.71). There was no significant correlation between PSA velocity and urinary levels of daidzein (p=0.90), genistein (p=0.98), enterolactone (p=0.10) or equol (p=0.60). CONCLUSION: These data do not support the hypothesis that phytoestrogens prevent disease progression in men with localised prostate cancer.


Subject(s)
Phytoestrogens/metabolism , Phytoestrogens/urine , Prostatic Neoplasms/urine , Aged , Biopsy , Dietary Supplements , Disease Progression , Humans , Male , Middle Aged , Prospective Studies , Prostate/pathology , Prostate-Specific Antigen/biosynthesis , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/epidemiology , Treatment Outcome , United Kingdom
2.
J Agric Food Chem ; 49(9): 4364-71, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11559139

ABSTRACT

The crispness of fruits and vegetables is dependent, predominantly, on the maintenance of cell adhesion. There is a growing body of evidence to suggest that cell adhesion in plants is controlled at the edge of cell faces rather than across the entire cell surface. The aim of the current study has been to exploit antibody-labeling techniques in conjunction with methods that induce cell separation to explore the distribution of highly esterified and weakly esterified pectic polysaccharides on the cell surface. Potato parenchyma tissue was subjected to cooking and chemical treatments, which induced softening through cell separation. Scanning electron microscopy (SEM) revealed characteristic patterns on the surface of these separated cells, which outlined the imprint of neighboring cells. Monoclonal antibodies, JIM5 and JIM7, were used to locate weakly esterified and highly esterified pectin by silver-enhanced immunogold SEM. The edge-of-face structures labeled strongly with JIM5 but not JIM7, indicating that they contained polygalacturonic acid of low ester content. In addition, adhesion of the middle lamella to the face of the primary wall was found to differ from adhesion at the edge of each cell face. This, in conjunction with the antibody-labeling observations, complements previous transmission electron microscopy studies and is consistent with the edge-of-face regions having a specialist role in cell adhesion.


Subject(s)
Cell Adhesion/physiology , Cell Wall/ultrastructure , Pectins/analysis , Solanum tuberosum/cytology , Antibodies, Monoclonal , Cooking , Microscopy, Electron, Scanning
3.
Crit Care Med ; 28(5): 1431-8, 2000 May.
Article in English | MEDLINE | ID: mdl-10834691

ABSTRACT

OBJECTIVE: Desmethyl tirilazad is a lipid-soluble free radical quencher. Deferoxamine reduces free radicals by chelating iron and reducing hydroxyl formation. Free radical inhibitors have shown promise in several hypoxic ischemic brain injury models, and we wished to see if this work could be extended to our newborn piglet model. DESIGN: Randomized controlled trial. SUBJECTS: Piglets (0 to 3 days old). INTERVENTION: Carotid snares and arterial and venous catheters were placed under 1.5% isoflurane anesthesia. In Experiment 1, piglets were randomly assigned to receive either 3 mg/kg desmethyl tirilazad or vehicle at -15 and 90 mins. In Experiment 2, piglets were randomly assigned to receive either 20 mg/kg desmethyl tirilazad at -15 mins followed by 8 mg/kg/hr for 90 mins or 100 mg/kg deferoxamine at -15 mins or vehicle. At time 0, both carotid arteries were clamped and blood was withdrawn to reduce the blood pressure to two-thirds normal. At 15 mins, inspired oxygen was reduced to 6%. At 30 mins, the carotid snares were released, the withdrawn blood was reinfused, and the oxygen was switched to 100%. On the third day after the hypoxic ischemic injury, the animals were killed by perfusing their brains with 10% formalin. We tested the timing of lipid peroxidation and inhibition of lipid peroxidation by these agents by freezing the brains of a subset of pigs in liquid nitrogen. MEASUREMENTS: Neurologic examination and brain pathology were scored by blinded observers. Thiobarbituric acid-reactive substance and oxidized and reduced glutathione were measured on frozen brains. MAIN RESULTS: Desmethyl tirilazad (20 mg/kg) and 100 mg/kg deferoxamine inhibit lipid peroxidation. Desmethyl tirilazad (20 mg/kg) improves neurologic exam, but 3 mg/kg Desmethyl tirilazad or 100 mg/kg deferoxamine does not. Neither desmethyl tirilazad nor deferoxamine improves pathologic results. CONCLUSIONS: High-dose desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in the newborn piglet.


Subject(s)
Antioxidants/pharmacology , Asphyxia Neonatorum/physiopathology , Hypoxia, Brain/physiopathology , Lipid Peroxidation/drug effects , Neurologic Examination/drug effects , Pregnatrienes/pharmacology , Animals , Animals, Newborn , Asphyxia Neonatorum/pathology , Brain/blood supply , Brain/pathology , Deferoxamine/pharmacology , Dose-Response Relationship, Drug , Humans , Hypoxia, Brain/pathology , Infant, Newborn , Lipid Peroxidation/physiology , Reactive Oxygen Species/metabolism , Reperfusion Injury/pathology , Reperfusion Injury/physiopathology , Swine
4.
Crit Care Med ; 21(2): 252-9, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8428478

ABSTRACT

OBJECTIVE: To determine if polyethylene glycol-bound superoxide dismutase and catalase and nimodipine, alone or in combination, will ameliorate hypoxic ischemic injury to the brain. SUBJECTS: A total of 78 newborn (0 to 3 days) pigs were used. DESIGN: Prospective, blinded, randomized, controlled trial. INTERVENTIONS: The piglets were subjected to hypoxic ischemic brain injury. Carotid arteries were ligated at time 0 and BP was reduced one third by hemorrhage. At 15 mins, FIO2 was reduced to 0.6. At 30 mins, carotids were released, blood was reinfused, and FIO2 was increased to 1.0. Pigs were randomly assigned at time 35 mins to receive either: 10,000 U/kg of polyethylene glycol-bound superoxide dismutase and catalase (group 1); 0.5 mg/kg of nimodipine (group 2); both 10,000 U/kg of superoxide dismutase and catalase and 0.5 mg/kg of nimodipine (group 3); or no drugs (controls). MEASUREMENTS: The time after reoxygenation for return of electroencephalogram, respiration, blink and pain were recorded in minutes as well as a neurologic examination at 1, 2, and 3 days and pathologic examination of the brain at 3 days, both by blinded observers. MAIN RESULTS: There were no significant differences in the four groups. CONCLUSIONS: Polyethylene glycol-bound superoxide dismutase and catalase, and nimodipine, either alone or in combination, do not ameliorate hypoxic ischemic injury to the brain in the newborn pig when given 5 mins after reoxygenation.


Subject(s)
Brain Ischemia/prevention & control , Catalase/therapeutic use , Hypoxia/prevention & control , Nimodipine/therapeutic use , Polyethylene Glycols/therapeutic use , Superoxide Dismutase/therapeutic use , Animals , Animals, Newborn , Blood Glucose , Blood Pressure , Body Temperature , Brain Ischemia/pathology , Catalase/administration & dosage , Lactates/blood , Nimodipine/administration & dosage , Polyethylene Glycols/administration & dosage , Prospective Studies , Random Allocation , Superoxide Dismutase/administration & dosage , Swine
5.
Crit Care Med ; 20(9): 1309-14, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1521447

ABSTRACT

BACKGROUND AND METHODS: Fructose-1,6-bisphosphate has been shown to improve the outcome of hypoxic ischemic brain injury in adult rabbits. We wished to see if these results could be extended to a newborn animal. Twenty-four 0- to 3-day-old piglets were randomized to receive 300 mg/kg of fructose-1,6-bisphosphate 5 mins before injury, followed by a continuous infusion of 15 mg/kg/min of fructose-1,6-bisphosphate for the next 90 mins, or the equivalent volume of normal saline. Hypoxic ischemic central nervous system damage was induced by ligating both carotid arteries and reducing their BP to two thirds of the normal value for 30 mins. In the last 15 mins of this 30 mins, the FIO2 was reduced to 0.6. At 30 mins, the piglets were resuscitated with an FIO2 of 1.0, the carotid ligatures were released, and the removed blood was reinfused. RESULTS: The neurologic examination scores at 1, 2, and 3 days after injury and pathologic examination scores at 3 days after injury were not different in the fructose-1,6-bisphosphate-treated and the control animals. CONCLUSION: Fructose-1,6-bisphosphate does not ameliorate hypoxic ischemic brain injury in the newborn pig.


Subject(s)
Brain Ischemia/drug therapy , Fructosediphosphates/administration & dosage , Hypoxia, Brain/drug therapy , Swine Diseases/drug therapy , Animals , Animals, Newborn , Brain/pathology , Brain Ischemia/blood , Brain Ischemia/pathology , Disease Models, Animal , Drug Evaluation, Preclinical , Fructosediphosphates/blood , Hypoxia, Brain/blood , Hypoxia, Brain/pathology , Swine , Swine Diseases/blood , Swine Diseases/pathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL